Moshe Mendelson, OD
Optometry · Sunnyvale
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 7
- 3 carriers
- Office
- 1
Offices
1 location · Mendelson and Mark Optometric Corporation · 8 clinicians in this group
Looking this up.
Plans that list them
7 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Mendelson’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
7 of 7 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
Original Medicare doctor bills
$10,535
Medicare paid this office $10,535 for 75 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 49 | $5,275 | $108 |
| Established patient problem focused exam of visual system | 20 | $1,762 | $84 |
| Short return visit (20+ min) | 11 | $904 | $70 |
| Photography of the retina | 12 | $377 | $31 |
Who their Medicare patients are
75 Original Medicare patients in 2024. Average age 75 · Women 61% · Health risk score 0.88. At or below the middle of the specialty; the typical optometry clinician is at 0.97.
Conditions among them: High blood pressure 68% · Diabetes 28% · Coronary heart disease 21% · Chronic kidney disease 21% · Cancer 20% · Heart failure 15%.
The office billed $25,879, Medicare allowed $15,667 and paid $10,535; for 132 services of 17 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 75 | 132 | 75 | 0.88 | $25,879 | $10,535 |
| 2023 | 83 | 152 | 74 | 0.73 | $27,637 | $12,666 |
| 2022 | 95 | 143 | 74 | 0.80 | $26,751 | $12,046 |
| 2021 | 93 | 161 | 74 | 0.77 | $28,420 | $14,419 |
| 2020 | 40 | 68 | 75 | 0.81 | $13,006 | $4,022 |
| 2019 | 88 | 159 | 73 | 0.72 | $34,844 | $13,613 |
| 2018 | 103 | 239 | 73 | 0.86 | $48,953 | $17,681 |
| 2017 | 79 | 174 | 74 | 0.85 | $33,032 | $12,400 |
| 2016 | 95 | 190 | 73 | 0.78 | $33,489 | $12,619 |
| 2015 | 74 | 140 | 73 | 0.82 | $25,202 | $10,393 |
| 2014 | 93 | 232 | 73 | 0.78 | $35,677 | $14,421 |
| 2013 | 122 | 266 | 75 | 0.82 | $40,318 | $16,498 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Established patient complete exam of visual system | 58 | $6,582 | $112 |
| Established patient problem focused exam of visual system | 18 | $1,594 | $80 |
2022: 2 services
| Established patient complete exam of visual system | 60 | $6,280 | $103 |
| Established patient problem focused exam of visual system | 31 | $3,243 | $77 |
2021: 3 services
| Established patient complete exam of visual system | 60 | $7,126 | $117 |
| Established patient problem focused exam of visual system | 30 | $3,312 | $87 |
| Photography of the retina | 13 | $456 | $35 |
2020: 2 services
| Established patient complete exam of visual system | 21 | $1,694 | $81 |
| Established patient problem focused exam of visual system | 11 | $927 | $62 |
2019: 2 services
| Established patient complete exam of visual system | 62 | $6,743 | $109 |
| Established patient problem focused exam of visual system | 22 | $2,931 | $79 |
2018: 5 services
| Established patient complete exam of visual system | 58 | $5,720 | $97 |
| Established patient problem focused exam of visual system | 40 | $4,469 | $80 |
| Return visit (30+ min) | 13 | $1,510 | $89 |
| Exam of visual field with extended testing | 19 | $1,327 | $55 |
| Imaging of optic nerve | 11 | $358 | $28 |
2017: 4 services
| Established patient complete exam of visual system | 56 | $5,759 | $103 |
| Established patient problem focused exam of visual system | 22 | $1,931 | $74 |
| Exam of visual field with extended testing | 15 | $1,000 | $56 |
| Imaging of optic nerve | 15 | $637 | $34 |
2016: 4 services
| Established patient complete exam of visual system | 58 | $5,357 | $91 |
| Established patient problem focused exam of visual system | 33 | $2,866 | $72 |
| Exam of visual field with extended testing | 18 | $1,205 | $57 |
| Imaging of optic nerve | 15 | $584 | $36 |
2015: 5 services
| Established patient complete exam of visual system | 48 | $4,875 | $102 |
| Established patient problem focused exam of visual system | 16 | $1,067 | $67 |
| Exam of visual field with extended testing | 15 | $995 | $62 |
| Photography of the retina | 12 | $866 | $72 |
| Short return visit | 11 | $454 | $41 |
2014: 7 services
| Established patient complete exam of visual system | 58 | $5,235 | $90 |
| Established patient problem focused exam of visual system | 21 | $1,743 | $67 |
| Exam of visual field with extended testing | 22 | $1,624 | $60 |
| Photography of the retina | 19 | $1,369 | $72 |
| Imaging of retina | 18 | $824 | $43 |
| Short return visit | 14 | $701 | $39 |
| Imaging of optic nerve | 17 | $679 | $36 |
2013: 9 services
| Established patient complete exam of visual system | 74 | $7,398 | $100 |
| Short return visit (20+ min) | 22 | $1,389 | $53 |
| Photography of the retina | 19 | $1,227 | $65 |
| Exam of visual field with extended testing | 15 | $1,168 | $65 |
| Short return visit | 20 | $1,129 | $42 |
| Established patient problem focused exam of visual system | 14 | $994 | $55 |
| Imaging of retina | 24 | $974 | $37 |
| Imaging of optic nerve | 21 | $830 | $38 |
| Ultrasound scan of cornea to determine thickness | 12 | $160 | $13 |
Drugs they prescribed that Part D paid
$17,174
Pharmacies billed $17,174 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 57) in 2024. At or below the middle of the specialty; the typical optometry clinician is at 0%.
15 generic and 42 brand-name prescriptions · $17,174 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Latanoprost | 28 | $433 | $15 |
Year by year
| 2024 | 57 | 13 | 0% (0) | 74% | $17,174 |
| 2023 | 59 | 18 | 0% (0) | 81% | $21,896 |
| 2022 | 52 | 21 | 0% (0) | 79% | $20,683 |
| 2021 | 37 | 21 | 0% (0) | 76% | $16,980 |
| 2020 | 51 | 14 | 0% (0) | 90% | $27,072 |
| 2019 | 33 | 11 | 0% (0) | 76% | $15,340 |
| 2018 | 57 | 24 | 0% (0) | 84% | $24,394 |
| 2017 | 57 | 26 | 0% (0) | 84% | $17,394 |
| 2016 | 61 | 23 | 0% (0) | 64% | $15,268 |
| 2015 | 43 | 13 | 0% (0) | 72% | $15,945 |
| 2014 | 51 | 17 | None | 92% | $19,027 |
| 2013 | 73 | 24 | 0% (0) | 73% | $17,215 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Cequa | 12 | $11,872 | $989 |
| Loteprednol Etabonate | 14 | $2,849 | $203 |
2022: 1 drug
| Xiidra | 11 | $6,804 | $619 |
2021: 1 drug
| Xiidra | 13 | $10,024 | $771 |
2020: 2 drugs
| Xiidra | 19 | $13,702 | $721 |
| Restasis | 16 | $11,957 | $747 |
2018: 2 drugs
| Xiidra | 19 | $10,744 | $565 |
| Restasis | 11 | $9,773 | $888 |
2017: 1 drug
| Restasis | 22 | $12,140 | $552 |
2016: 2 drugs
| Restasis | 24 | $12,862 | $536 |
| Latanoprost | 21 | $327 | $16 |
2015: 1 drug
| Restasis | 27 | $14,586 | $540 |
2014: 2 drugs
| Restasis | 23 | $14,443 | $628 |
| Lumigan | 15 | $2,286 | $152 |
2013: 2 drugs
| Restasis | 30 | $11,047 | $368 |
| Latanoprost | 12 | $160 | $13 |
Money from drug and device companies
$1,046 in 2025
| 2025 | 3 | 8 | $750 | $1,046 |
| 2024 | 9 | 26 | $413 | $1,381 |
| 2023 | 8 | 32 | $3,163 | $5,375 |
| 2022 | 9 | 39 | $6,800 | $8,570 |
| 2021 | 9 | 38 | $5,300 | $6,019 |
| 2020 | 9 | 21 | $3,438 | $3,746 |
| 2019 | 7 | 18 | None | $645 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Johnson & Johnson Vision Care | Acuvue | $750 | 1 payment
|
| Alcon Vision | Hydrus Microstent | $232 | 5 payments
|
| Dompe US | Oxervate | $65 | 2 payments
|
See all 8 published payments
| Dompe US | Meals · 2025-11-10 | Oxervate | $33 |
| Alcon Vision | Meals · 2025-11-04 | Tryptyr | $15 |
| Alcon Vision | Meals · 2025-07-08 | Eysuvis | $26 |
| Alcon Vision | Meals · 2025-06-17 | Hydrus Microstent | $159 |
| Johnson & Johnson Vision Care | Consulting · 2025-05-29 | Acuvue | $750 |
| Alcon Vision | Meals · 2025-03-04 | Precision7 | $12 |
| Dompe US | Meals · 2025-02-18 | Oxervate | $32 |
| Alcon Vision | Meals · 2025-01-29 | Eysuvis | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,381
| Johnson & Johnson Vision Care | Acuvue | $554 | 4 payments
|
| Biotissue Holdings | None | $198 | 7 payments
|
| Visioneering Technologies | None | $190 | 1 payment
|
| Lumenis BE | Optilight | $190 | 1 payment
|
| Alcon Vision | Dailies Total1 | $104 | 5 payments
|
| Bausch & Lomb Americas | Miebo | $98 | 5 payments
|
| Tarsus Pharmaceuticals | Xdemvy | $18 | 1 payment
|
| CooperVision | Misight Contact Lens | $16 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $14 | 1 payment
|
2023: $5,375
| Johnson & Johnson Vision Care | Acuvue | $4,701 | 15 payments
|
| Sun Pharmaceutical Industries | Cequa | $317 | 8 payments
|
| Oyster Point Pharma | Tyrvaya | $212 | 2 payments
|
| Alcon Vision | Eysuvis | $48 | 2 payments
|
| Horizon Therapeutics plc | Tepezza | $37 | 2 payments
|
| Dompe US | Oxervate | $21 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $19 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $19 | 1 payment
|
2022: $8,570
| Johnson & Johnson Vision Care | Acuvue | $8,159 | 20 payments
|
| Sun Pharmaceutical Industries | Cequa | $222 | 10 payments
|
| Allergan | Vuity | $43 | 2 payments
|
| Johnson & Johnson Surgical Vision | Lipiflow System Activator (Disposable) | $41 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $34 | 2 payments
|
| CooperVision | Multiple Brands Contact Lens | $23 | 1 payment
|
| Abbvie | Vuity | $21 | 1 payment
|
| Bausch & Lomb Americas | Alden Scleral Zenlens | $15 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $12 | 1 payment
|
2021: $6,019
| Johnson & Johnson Vision Care | Acuvue | $4,369 | 10 payments
|
| Johnson & Johnson Surgical Vision | None | $1,000 | 1 payment
|
| Novartis Pharmaceuticals | Xiidra | $151 | 9 payments
|
| Lumenis BE | M22 | $149 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $125 | 10 payments
|
| CooperVision | Misight Contact Lens | $99 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $78 | 4 payments
|
| Lumenis | Lumenis Pulse 120h | $25 | 1 payment
|
| Visioneering Technologies | None | $24 | 1 payment
|
2020: $3,746
| Johnson & Johnson Vision Care | Acuvue | $2,951 | 5 payments
|
| CooperVision | Misight Contact Lens | $512 | 3 payments
|
| Sun Pharmaceutical Industries | Cequa | $106 | 5 payments
|
| Novartis Pharmaceuticals | Xiidra | $59 | 3 payments
|
| Dompe US | Oxervate | $30 | 1 payment
|
| Allergan | Restasis | $26 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $24 | 1 payment
|
| TissueTech | Prokera | $20 | 1 payment
|
| Carl Zeiss Meditec | None Specified | $17 | 1 payment
|
2019: $645
| Shire North American Group | Xiidra | $304 | 9 payments
|
| Visioneering Technologies | None | $127 | 1 payment
|
| Johnson & Johnson Vision Care | Acuvue | $102 | 2 payments
|
| Novartis Pharmaceuticals | Xiidra | $66 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Besivance | $22 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $20 | 1 payment
|
| ABB Con-Cise Optical Group | Contact Lens | $5 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Bausch Health US, LLC · Study Is To Evaluate the Product Performance of Kalifilcon A Contact Lenses Compared To 1-Day Acuvue Oasys With Hydralux Contact Lenses and Clariti 1 Day Contact Lenses · 2019 | This clinician | $9,300 |
| Bausch Health US, LLC · A Study To Evaluate the Safety, Effectiveness and Product Performance of the Biotrue Oneday for Astigmatism Soft Contact Lens When Worn on A Daily Basis · 2019 | This clinician | $6,180 |
Professional record
- NPI
- 1366443277
- Licence
- CA OPT9629T
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 152W00000X (152W00000X)
- Mailing address
- 1010 W Fremont Ave, Suite #200, Sunnyvale, CA, 94087
- NPI first listed
- 2005-08-02
- NPI last updated
- 2014-02-28
This is when the NPI record was last certified, not a medical board exam.